PDL BIOPHARMA, INC. 4
4 · PDL BIOPHARMA, INC. · Filed Mar 7, 2017
Insider Transaction Report
Form 4
Stone Christopher Lewis
VP and General Counsel
Transactions
- Award
Common stock
2017-03-04$2.04/sh+214,372$437,319→ 448,746 total
Footnotes (1)
- [F1]The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved, based upon the following schedule: 50% on December 2018; 16.66% on December 2019; 16.66% on December 2020; and 16.66% on December 2021.